Drug Discovery

RQ Bio secures $115m to develop influenza antibody programme

UK-based RQ Bio has closed a £85.5m ($115m) Series A funding round to advance its long-acting antibody therapeutic programme RQB01, which targets influenza prevention in high-risk and immunocompromised groups.

Boehringer and Combotope partner for cancer antibodies

Boehringer Ingelheim has signed a research collaboration agreement with Combotope Therapeutics to advance tumour-selective antibody therapies targeting cancer.

Haisco and Nuvectis sign licensing deal for two drugs

Haisco Pharmaceutical Group has signed an exclusive licensing agreement granting US-based biotechnology company Nuvectis rights for two drug candidates in oncology and complement indications.

Genprex’s Reqorsa combo secures Canadian patent for lung cancer

Genprex has received a notice of allowance from the Canadian Intellectual Property Office (CIPO) for a patent related to the use of its Reqorsa Gene Therapy (quaratusugene ozeplasmid) in combination with either programmed cell death protein 1 (PD-1) or PD-L1 antibodies to treat non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

Lilly and BioArctic sign deal to develop neurodegenerative therapy

Eli Lilly and Company has signed a research and collaboration agreement with Swedish biopharmaceutical company BioArctic to develop a potential treatment for neurodegenerative diseases.

Sun Pharma to acquire Innovcare Lifesciences for $28.7m

Sun Pharmaceutical Industries has agreed to purchase India-based Innovcare Lifesciences in a deal valued at approximately Rs2.71bn ($28.7m).

Voro and Alloy partner on tumour-selective TCE therapeutics

Voro Therapeutics and Alloy Therapeutics have formed a strategic research partnership to develop tumour-selective, next-generation masked T-cell engager (TCE) therapeutics.

Biogen to acquire RayThera for up to $1bn

Biogen has entered a definitive agreement to acquire RayThera, a biotechnology company specialising in small-molecule therapies for immunology, for up to $1bn.

Jazz and AbCellera sign deal for T-cell engagers in solid tumours

Jazz Pharmaceuticals and AbCellera have signed a preclinical research, option, and licence agreement for the discovery and development of T-cell-engaging multispecific antibodies, or T-cell engagers (TCEs), for gastrointestinal (GI) cancers and other solid tumours.